C.M.P. O'Tuathaigh
Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies
O'Tuathaigh, C.M.P.; Moran, P.M.; Zhen, X.C.; Waddington, J.L.
Authors
P.M. Moran
X.C. Zhen
J.L. Waddington
Abstract
The presence and severity of cognitive symptoms, including working memory, executive dysfunction and attentional impairment, contributes materially to functional impairment in schizophrenia. Cognitive symptoms have proven resistant to both first- and second-generation antipsychotic drugs. Efforts to develop a consensus set of cognitive domains that are both disrupted in schizophrenia and are amenable to cross-species validation (e.g. the NIMH CNTRICS and RDoC initiatives) are an important step towards standardisation of outcome measures that can used in preclinical testing of new drugs. While causative genetic mutations have not been identified, new technologies have identified novel genes as well as hitherto candidate genes previously implicated in the pathophysiology of schizophrenia and/or mechanisms of antipsychotic efficacy. This review comprises a selective summary of these developments, particularly phenotypic data arising from preclinical genetic models for cognitive dysfunction in schizophrenia, with the aim of indicating potential new directions for pro-cognitive therapeutics.
Citation
O'Tuathaigh, C., Moran, P., Zhen, X., & Waddington, J. (in press). Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies. British Journal of Pharmacology, 174(19), https://doi.org/10.1111/bph.13938
Journal Article Type | Article |
---|---|
Acceptance Date | Jun 12, 2017 |
Online Publication Date | Aug 3, 2017 |
Deposit Date | Jun 21, 2017 |
Publicly Available Date | Mar 29, 2024 |
Journal | British Journal of Pharmacology |
Print ISSN | 0007-1188 |
Electronic ISSN | 1476-5381 |
Publisher | Wiley |
Peer Reviewed | Peer Reviewed |
Volume | 174 |
Issue | 19 |
DOI | https://doi.org/10.1111/bph.13938 |
Public URL | https://nottingham-repository.worktribe.com/output/876522 |
Publisher URL | http://onlinelibrary.wiley.com/doi/10.1111/bph.13938/abstract |
Additional Information | This is the peer reviewed version of the following article: O'Tuathaigh, C. M. P., Moran, P. M., Zhen, X. C., and Waddington, J. L. (2017) Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies. British Journal of Pharmacology, doi: 10.1111/bph.13938 which has been published in final form at http://onlinelibrary.wiley.com/doi/10.1111/bph.13938/full This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. |
Files
bjp.pdf
(228 Kb)
PDF
You might also like
Does cannabis use predict psychometric schizotypy via aberrant salience?
(2020)
Journal Article
Olfactory threshold selectively predicts positive psychometric schizotypy
(2019)
Journal Article
Pharmacology of cognition : a panacea for neuropsychiatric disease
(2017)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: digital-library-support@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search